Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Neuro-Oncology|June 3, 2017
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplificationJuan Manuel Sepúlveda-Sánchez, María Ángeles Vaz, Carmen Balañá, et al.
Frontiers in Medicine|November 21, 2022
Progression to lung fibrosis in severe COVID-19 patients: A morphological and transcriptomic study in postmortem samplesBelén Pérez-Mies, Tamara Caniego-Casas, Tommaso Bardi, et al.
European Journal of Cancer (Oxford, England : 1990)|January 8, 2025
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Tomás Pascual, Olga Martínez-Saez, et al.
Breast Cancer Research and Treatment|February 28, 2026
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Isabel García-Fructuoso, Tomás Pascual, et al.
Targeted Oncology|October 7, 2020
Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)Juan Manuel Sepúlveda-Sánchez, Miguel Gil-Gil, Miriam Alonso-García, et al.
The Journal of Experimental Medicine|April 13, 2019
Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF mutationSusana García-Silva, Alberto Benito-Martín, Sara Sánchez-Redondo, et al.
EMBO Molecular Medicine|February 17, 2022
A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasisLucía Zhu, Diana Retana, Pedro García-Gómez, et al.
Pageof 4